Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.12 | N/A | +46.23% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.12 | N/A | +46.23% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the company's progress in product expansion. They emphasized a commitment to growth and efficiency.
We are pleased with our progress in expanding our product offerings.
Our focus remains on driving growth and improving operational efficiency.
Veracyte's earnings report shows a significant EPS surprise, indicating better-than-expected performance on that front. However, the lack of revenue data and no guidance update may leave investors uncertain about future growth. The stock reacted negatively, declining by 1.67%, likely reflecting concerns over the absence of revenue figures and guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BARRICK MNG CORP
Oct 26, 2018